Discover the interview of Séverine Sigrist, the Chief Executive and Scientific Officer of Defymed. She will present you the Defymed Company and the ExOlin® medical device.

The aim of the medical devices developed by Defymed is to respond to the request of the diabetic patients by allowing a more physiological treatment of diabetes.
For ExOlin®, the first clinical trial will prove safety and early performance of the device. The objective is to obtain CE-mark after the achievement of a more important clinical trial in different European states.
ExOlin® is a therapeutic innovation allowing a response to many patients at a global level. To enable a large-scale commercialization of the device, Defymed wishes to transfer a business license to a big medtech.

Do not hesitate to share this video on your social media and to follow us on LinkedIn, Twitter and Facebook!

For more information or for any enquiry send us your questions at

Thanks to Carole Nouchi and AMS CONCEPT for the achievement of the editing of the video.